$6.10
2.40%
Nasdaq, Mon, Oct 26 2026.
ISIN
US14888D2080
Symbol
CSCI

Catalyst Biosciences, Inc. Stock price

$6.10
-0.36 5.57% 1M
+0.25 4.27% 6M
-0.08 1.29% YTD
-1.40 18.67% 1Y
-11.54 65.42% 3Y
-178.04 96.69% 5Y
-1,247.90 99.51% 10Y
-1,106,671.88 100.00% 20Y
Nasdaq, Closing price Mon, Oct 26 2026
-0.15 2.40%
ISIN
US14888D2080
Symbol
CSCI
Industry

Is Catalyst Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.3m
Enterprise Value
$3.0m
Net debt
positive
Cash
$5.3m
Shares outstanding
1.1m
Valuation
P/E
1.0
P/S | estimate
0.8 | -
EV/Sales | estimate
0.4 | -
EV/FCF | ex SBC
negative | negative
P/B
0.4
Financial Health
Equity Ratio
17.9%
Return on Equity
-269.6%
ROCE
-30.2%
ROIC
-42.7%
Debt/Equity
0.1
Financials
Revenue | estimate
$8.3m | -
EBITDA
$-3.8m
EBIT
$-5.0m
Net Income
$6.6m
Free Cash Flow | ex SBC
$-3.8m | $-3.8m
Growth
Revenue | estimate
-12.3% | -
EBITDA
78.1%
EBIT
73.1%
Net Income
134.8%
Free Cash Flow
79.2%
Margin
Gross
45.4%
EBITDA
-45.5%
EBIT
-60.6%
Net
79.1%
Free Cash Flow | ex SBC
-45.6% | -45.6%
More
EPS
$6.3
FCF per Share
$-3.6
Short interest
0.3%
Employees
28
Rev per Employee
$270.0k

Catalyst Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Catalyst Biosciences, Inc.

Jun '26
+/-
%
8.28 8.28
12% 12%
100%
- Direct Costs 4.52 4.52
10% 10%
55%
3.76 3.76
15% 15%
45%
- Selling and Administrative Expenses 7.03 7.03
37% 37%
85%
- Research and Development Expense 1.43 1.43
81% 81%
17%
-3.77 -3.77
78% 78%
-46%
- Depreciation and Amortization 1.25 1.25
16% 16%
15%
EBIT (Operating Income) EBIT -5.02 -5.02
73% 73%
-61%
Net Profit 6.55 6.55
135% 135%
79%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
●
12 days ago
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tum...
Neutral
GlobeNewsWire
●
21 days ago
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 81,525 shares ...
Neutral
GlobeNewsWire
●
22 days ago
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
More Catalyst Biosciences, Inc. News

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Puccetti
Employees 28
Founded 1997
Website www.cosciensbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today